Poster
Novel C-7 Carbon Substituted Fourth Generation Fluoroquinolones Targeting N.Gonorrhoea Infections
![](https://cdn.prod.website-files.com/6542715d273d7352ef084082/65be3344579cef4a250cf386_resources-header.jpg)
Fluoroquinolones (FQ) are a first-line antibacterial therapy, used to treat both Gram-negative and Gram-positive bacterial infections. FQ efficacy is achieved by disrupting the bacterial enzyme's DNA gyrase and topoisimerase IV. There is extensive SAR analysis of this class of antibiotics-both in terms of microbiological activity 1-3 and target related toxicity. Delafloxacin, a fourth generation FQ has broad spectrum activity and reduced FQ related toxicity 4-5. However, it has recently failed a phase 3 clinical trial for treatment of N.gonorrhoeae infections. This was due to lack of sufficient efficacy at the dose administered.
Alternatively, search our entire resource library below
![](https://cdn.prod.website-files.com/659db4dde7f13f395f49157c/65bde5f47f5edc2f327a5e56_Screenshot%202024-02-03%20at%2006.53.20.png)